ADVFN ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Fiona Craig

ITM Power Secures NEPTUNE II Contract with Leading Spanish Cement Producer

May 09 2025 @ 03:15
ITM Power (LSE:ITM) has announced the signing of a contract to supply its NEPTUNE II electrolyser system to a major Spanish cement producer. This deployment represents ITM’s first foray into the cement industry, where the company aims to help reduce CO2 emissions by integrating green hydrogen with natural gas during the cement production process. Revenue […]
 

HydrogenOne to Release Q1 2025 NAV and Portfolio Update

May 09 2025 @ 03:13
HydrogenOne Capital Growth plc (LSE:HGEN) has announced that it will release its Q1 2025 Net Asset Value (NAV) and portfolio update on 14 May 2025. To further engage shareholders and potential investors, the company will host a live presentation offering detailed insights into its recent performance and future outlook. This initiative underscores HydrogenOne’s ongoing commitment […]
 

Tiger Royalties Enters Decentralised AI with £250,000 Investment

May 09 2025 @ 03:12
Tiger Royalties and Investments Plc (LSE:TIR) has taken a significant step into the decentralised AI sector, signing a Letter of Intent to invest £250,000 in Tao Strategies Singapore. This investment will allow Tiger to enter the Bittensor network, an open-source blockchain marketplace designed for machine learning models. Through this strategic move, Tiger aims to position […]
 

Physiomics Ventures into Rheumatoid Arthritis with New UK Contract

May 09 2025 @ 03:11
Physiomics plc (LSE:PYC) has entered the rheumatoid arthritis field by securing a contract with a UK-based client to apply its population Pharmacokinetic modelling techniques to Phase 1 clinical data for a small molecule aimed at treating the condition. The £67,500 contract, expected to be completed within three months, represents Physiomics’ first foray into rheumatoid arthritis […]
 

Ondine Biomedical Names Alan Thomas as Interim CFO

May 09 2025 @ 03:10
Ondine Biomedical Inc. (LSE:OBI) has appointed Alan Thomas as its interim Chief Financial Officer, stepping in for Michael Behlke, who has stepped down due to personal reasons. Thomas, who will not join the Board, brings over 25 years of senior financial leadership experience within the healthcare and biotech industries. His previous roles include CFO positions […]
 

CEPS PLC Extends Loan Term, Raises Interest Rate

May 09 2025 @ 03:09
CEPS PLC (LSE:CEPS) has extended the maturity of a third-party loan originally arranged in 2021, now set for repayment by June 2026. As part of the new terms, the loan’s annual interest rate will increase from 7% to 9%. The extension constitutes a related party transaction, as the loan is backed by a personal guarantee […]
 

Ocean Harvest Technology Issues Funding Update as Default Risk Looms

May 09 2025 @ 03:08
Ocean Harvest Technology Group Plc (LSE:OHT) has released an update regarding its current funding position, following an earlier disclosure. The company is actively working with shareholders—including secured loan note holders—to secure a financial solution. While certain recent developments could technically constitute a default under existing loan agreements, no creditors have yet exercised...
 

Genflow Biosciences Raises £500K to Progress Dog Aging Study

May 09 2025 @ 03:07
Genflow Biosciences Plc (LSE:GENF) has secured £500,000 in funding through a new share subscription, earmarked to support the next phase of its canine longevity study. The trial, which is investigating the safety and potential benefits of the company’s therapeutic candidate in older dogs, aims to enhance muscle strength and reduce biological markers associated with aging. […]
 

AstraZeneca Reports Positive Imfinzi Results in Bladder Cancer Trial

May 09 2025 @ 03:06
AstraZeneca (LSE:AZN) has unveiled encouraging data from its Phase III POTOMAC trial, where the cancer immunotherapy Imfinzi demonstrated a notable improvement in disease-free survival among patients with high-risk non-muscle-invasive bladder cancer. The regimen, which combines Imfinzi with BCG therapy, offers a promising new option for early-stage bladder cancer patients. The safety profile...
 

Northern Bear Names Julian Davis as New CFO

May 09 2025 @ 03:05
Northern Bear plc (LSE:NTBR) has appointed Julian Davis as its new Chief Financial Officer, effective immediately. With a strong background in the construction and housebuilding industries, Davis is expected to play a key role in driving the company’s financial strategy and supporting its continued growth. His expertise is anticipated to strengthen both operational execution and […]
 
 
Do you want to write for our Newspaper? Get in touch: newspaper@advfn.com